CAD 1833

Drug Profile

CAD 1833

Alternative Names: CAD1833

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cadent Therapeutics; Saniona
  • Developer Cadent Therapeutics
  • Class Antiparkinsonians; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Small conductance calcium activated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ataxia; Essential tremor

Most Recent Events

  • 12 Mar 2018 Phase-I clinical trials in Ataxia in USA (unspecified route)
  • 12 Mar 2018 Phase-I clinical trials in Essential tremor in USA (unspecified route)
  • 03 Nov 2017 Preclinical trials in Essential tremor in USA before November 2017 (Candent Therapeutics pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top